Rhabdomyolysis with Co-Administration of Statins and Antiplatelet Therapies —Analysis of the WHO Pharmacovigilance Database

ConclusionRhabdomyolysis reporting was increased when ticagrelor -but not other antiplatelet agents- was notified with the most prescribed statins in practice. This finding needs to be considered by physicians especially in high-risk patients.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research